{
    "SPADE_UN_14339": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_14339",
            "Peptide Name": "LP-67",
            "Source": "Synthetic construct",
            "Family": "Retroviridae",
            "Gene": "Not found",
            "Sequence": "LLEQAEEQQKKNEEELKKLEX",
            "Sequence Length": 21,
            "UniProt Entry": [
                "http://www.uniprot.org/uniprot/P03377"
            ],
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Antimicrobial",
                "Antiviral"
            ],
            "Target Organism": "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=3417±419 pM);HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=627±154 pM);HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1527±565 pM).",
            "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry",
            "Cytotoxicity": "No cytotoxicity information or data found in the reference(s) presented in this entry",
            "Binding Target": "membrane",
            "Linear/Cyclic": "Linear",
            "N-terminal Modification": "Acetylation",
            "C-terminal Modification": "Amidation",
            "Stereochemistry": "L",
            "Structure Description": "Not found",
            "Formula": "C105H176N28O38",
            "Mass": 2568.06,
            "PI": 4.6,
            "Net Charge": -3,
            "Hydrophobicity": -1.767,
            "Half Life": "Mammalian:5.5 hourYeast:3 minE.coli:2 min",
            "Mechanism of action": "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",
            "Literature": [
                {
                    "Title": "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",
                    "Pubmed ID": "30089693",
                    "Reference": "J Virol. 2018 Sep 26;92(20)e01088-18.",
                    "Author": "Chong H, Zhu Y, Yu D, He Y.",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=30089693"
                }
            ],
            "Frequent Amino Acids": "EKL",
            "Absent Amino Acids": "CDFGHIMOPRSTUVWY",
            "Basic Residues": 4,
            "Acidic Residues": 7,
            "Hydrophobic Residues": 5,
            "Polar Residues": 9,
            "Positive Residues": 4,
            "Negative Residues": 7,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_14340",
                    "Similarity": 1.0,
                    "Sequence": "AEEQQKKNEEELKKLE"
                },
                {
                    "SPADE_ID": "SPADE_UN_14334",
                    "Similarity": 0.9,
                    "Sequence": "EQKIEELLKKAEEQQKKNEEELKKLE"
                },
                {
                    "SPADE_ID": "SPADE_UN_14335",
                    "Similarity": 0.9,
                    "Sequence": "QKIEELLKKAEEQQKKNEEELKKLE"
                }
            ]
        }
    }
}